Updated:
Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage Nasdaq-listed biotech developing pepinemab for Huntington's disease and cancer via its ActivMAb platform.
Vaccinex, Inc.
Vaccinex, Inc. was founded as a biotech developer and has operated as a publicly held company, trading on the Nasdaq under the ticker VCNX. Its origins trace to scientific work in antibody discovery and vaccine design, though the firm is not a family office or asset manager. The company's pipeline centers on pepinemab, an anti-semaphorin 4D antibody being evaluated in Phase 2 trials for Huntington's disease and various cancers. Vaccinex also applies its ActivMAb platform to generate monoclonal antibodies against challenging targets such as G protein-coupled receptors and ion channels. Geographically, the firm operates primarily from its headquarters in Rochester, New York, with clinical activities extending to the United States and Europe. Vaccinex disclosed approximately $12.7 million in cash and equivalents as of March 2025 (per SEC filing), with a market capitalization under $50 million. The firm employs a small team of researchers and executives, including CEO Maurice Zauderer. No philanthropic arms or investment vehicles have been disclosed. A genuine structural differentiator is Vaccinex's reliance on its ActivMAb platform for drug discovery, which combines yeast display with mammalian cell expression to target difficult antigens. This platform, rather than a traditional pipeline, represents the core asset and potential deal-making driver.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Vaccinex's primary drug candidate?
Pepinemab, a monoclonal antibody targeting semaphorin 4D, is in Phase 2 trials for Huntington's disease and multiple oncology indications (per SEC filings). The drug is designed to modulate immune responses in the brain and tumor microenvironment.
How does the ActivMAb platform work?
ActivMAb couples yeast display technology with mammalian cell protein expression to enable antibody discovery against difficult targets like GPCRs and ion channels. The platform allows for functional screening of antibodies in a native-like conformation (per the company's corporate presentations).
Is Vaccinex a family office or an investment firm?
No. Vaccinex, Inc. (ticker VCNX) is a publicly traded biotechnology company focused on therapeutics and vaccine development. It does not manage external capital or function as a family office.
What is the company's financial position?
As of March 31, 2025, Vaccinex reported about $12.7 million in cash and equivalents (per SEC 10-Q). The firm has historically funded operations through equity offerings, partnerships, and grants.
Does Vaccinex have any commercial products?
No. All candidates are in clinical stages. The firm has not yet received FDA approval for any product.
Who leads Vaccinex?
Maurice Zauderer serves as President and CEO. The scientific leadership includes co-founders from the University of Rochester, where the underlying technology originated (per the firm's SEC filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: